LOUIS M. ALEDORT, M.D.; RICHARD A. LIPTON, M.D.; MARGARET HILGARTNER, M.D.
Clotting-factor therapy is a costly part of comprehensive hemophilia treatment. Physicians treating patients with hemophilia in New York formed a consortium for the purchasing and regional distribution of clotting-factor concentrates. Concentrates are centrally purchased based on a bidding formula aimed at obtaining the lowest price for quality product while guaranteeing all suppliers continued involvement in a large market area. The consortium has successfully maintained, and, in instances, lowered prices each year. Estimated regional savings this year are more than $750 000 for an anticipated purchase of approximately 60 000 000 units of clotting-factors VIII and IX. Central distribution has additionally lowered costs to participating hospitals. The consortium is able to provide patients and third-party payers with some of the lowest prices for clotting-factor concentrates in the United States. A physician-directed regional approach to purchasing costly medical products might be applied to other areas of clinical medicine.
Learn more about subscription options.
Register Now for a free account.
ALEDORT LM, LIPTON RA, HILGARTNER M. A Consortium for Purchase of Blood Products Directed by Physicians. Ann Intern Med. 1988;108:754–756. doi: 10.7326/0003-4819-108-5-754
Download citation file:
Published: Ann Intern Med. 1988;108(5):754-756.
Coagulopathies, Hematology/Oncology, Hospital Medicine.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only